Has Daniel Bensimhon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,486,715 in general payments to Daniel Bensimhon, MD across 1,525 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Bensimhon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Bensimhon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Bensimhon, MD

Advanced Heart Failure and Transplant Cardiology · Greensboro, NCNPI 1245293505

Payments from drug & device makers

$2,486,715in general payments, 2019–2025

Across 1,525 payments — averaging $1630.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sensible Medical Innovations Inc$318K
Actelion Pharmaceuticals US, Inc.$296K
Sensible Medical Innovations Ltd$284K
Boehringer Ingelheim$259K
Lilly USA, LLC$186K
GE HealthCare$168K
plus $976K from 42 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sensible Medical Innovations Inc	16	$318,225
Actelion Pharmaceuticals US, Inc.	268	$295,731
Sensible Medical Innovations Ltd	5	$283,827
Boehringer Ingelheim	230	$259,276
Lilly USA, LLC	137	$185,799
GE HealthCare	8	$167,900
Bayer	100	$147,142
Caption Health, Inc.	3	$120,026
Scpharmaceuticals Inc.	62	$105,373
AstraZeneca	114	$93,448
Novartis	90	$88,723
Irhythm Technologies, Inc.	54	$85,734
Pfizer	76	$71,539
Itamar Medical Inc	5	$43,827
Actelion Pharmaceuticals, Ltd	12	$43,400
Heartflow, Inc.	3	$41,261
E.r. Squibb & Sons, L.L.C.	38	$34,251
Merck	36	$33,793
Analog Devices Inc.	1	$32,285
Bridgebio Pharma, Inc.	6	$6,175
Baxter Healthcare	6	$5,544
Boston Scientific	9	$4,603
Novo Nordisk	3	$4,520
Medicure Pharma Inc.	1	$3,000
Eli Lilly	1	$3,000
Boehringer Ingelheim International GmbH	1	$2,125
Abbott	39	$1,263
Biotronik Inc.	3	$926
Johnson & Johnson	62	$874
Amgen	49	$752
Abiomed	20	$511
ZOLL Medical Corporation	1	$307
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	21	$295
Inari Medical, Inc.	1	$234
Medtronic(2 entities)	4	$181
United Therapeutics Corporation	11	$161
Cvrx, Inc.	7	$151
Alnylam Pharmaceuticals Inc.	1	$123
Arbor Pharmaceuticals, Inc.	6	$94
Kestra Medical Technology Services, Inc.	2	$74
Otsuka America Pharmaceutical, Inc.	3	$43
Portola Pharmaceuticals, LLC	2	$42
Vifor Pharma, Inc.	2	$34
Haemonetics Corporation	1	$31
Stryker	1	$29
Gilead	2	$27
Daiichi Sankyo Inc.	1	$25
Impulse Dynamics (USA) Inc.	1	$13

How this compares

$2,486,715 in reported general payments places this provider in the 95th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.

See all advanced heart failure and transplant cardiology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$104,069

Medicare patients

625

Services billed

1,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other advanced heart failure and transplant cardiology in Greensboro

Dalton McLeanGreensboro$706K
Benjamin StonerGreensboro$3K
David IshizawarRaleigh$1.2M
Stephen GreeneDurham$737K
Emil MissovGreenville$582K
Hassan AlhosainiWinston Salem$394K
John RommelWilmington$394K
Kishan ParikhRaleigh$318K
Stephen ZouzoulasConcord$244K
Benjamin TrichonAsheville$233K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →